New Methods Of Treatment Of Ovarian Cancer.
Women with advanced ovarian cancer who welcome strong chemotherapy without delay into their stomach area may live at least one year longer than women who earn standard intravenous chemotherapy, a inexperienced study says. But this survival edge may come at the cost of more side effects. "The long-term benefits are good-looking significant," said study author Dr Devansu Tewari, the man of gynecologic oncology at the Southern California Permanente Medical Group, in Orange County kamperen medicine. "There is no analysis of ovarian cancer treatments that has shown a greater survival advantage".
Intraperitoneal chemotherapy involves bathing the abdominal zone with chemotherapy agents. By contrast, intravenous (IV) chemotherapy is delivered throughout the body via the bloodstream muscleadvance. The US National Cancer Institute currently recommends intraperitoneal treatment for women with ovarian cancer who have had in the money surgery to disconnect the tumor.
The 10-year bolstering text from two studies of nearly 900 women with advanced ovarian cancer will be presented Saturday at the annual conclave of the Society of Gynecologic Oncology, in Los Angeles. In 2013, more than 22000 American women will be diagnosed with ovarian cancer, and more than 14000 will lose one's life from the disease, according to the US National Cancer Institute. There are no antediluvian screening tests for ovarian cancer, which is why it is often diagnosed when the cancer has already holding furthest of the ovaries.
For this reason, survival rates see to to be very low. In the recent study, women who received the intraperitoneal care were 17 percent more tenable to survive longer than those who got IV chemotherapy. On average, women in the intraperitoneal assemblage survived for more than five years, while those who received IV chemotherapy survived for about four years, the muse about found. But survival benefits aside, intraperitoneal chemotherapy does converse a greater imperil of side belongings - such as abdominal pain and numbness in the hands and feet - and not all women can put up with this high concentration of cancer-killing drugs.
The drugs are also preoccupied more slowly, providing more exposure to the medicine. The same properties that think the intraperitoneal therapy more effective likely enjoy oneself a role in causing more side effects, the researchers said. In general, six cycles of intraperitoneal chemotherapy are recommended, and can be given in inpatient or outpatient settings. The more cycles the women completed, the greater their survival advantage, the look at showed.
Показаны сообщения с ярлыком chemotherapy. Показать все сообщения
Показаны сообщения с ярлыком chemotherapy. Показать все сообщения
четверг, 14 марта 2019 г.
суббота, 17 ноября 2018 г.
Patients With Cancer Choose Surgery
Patients With Cancer Choose Surgery.
People with speech cancer who suffer surgery before receiving radiation care fare better than those who start treatment with chemotherapy, according to a small budding study. Many patients may be hesitant to begin their treatment with an invasive procedure, University of Michigan researchers noted. But advanced surgical techniques can correct patients' chances for survival, the authors well-known in a university word release bonuses. The study was published online Dec 26, 2013 in JAMA Otolaryngology Head and Neck Surgery.
Nearly 14000 Americans will be diagnosed with dialect cancer this year and 2,070 will go to one's final from the disease, according to the American Cancer Society. "To a puerile man with tongue cancer, chemotherapy may durable like a better option than surgery with extensive reconstruction," think over author Dr Douglas Chepeha, a professor of otolaryngology-head and neck surgery at the University of Michigan Medical School, said in the item release hair loss. "But patients with voiced pit cancer can't tolerate induction chemotherapy as well as they can handle surgery with consolidation radiation".
And "Our techniques of reconstruction are advanced and present oneself patients better survival and functional outcomes". The ruminate on involved 19 people with advanced oral cavity gob cancer. All of the participants were given an initial dose of chemotherapy (called "induction" chemotherapy). Patients whose cancer was reduced in dimensions by 50 percent received more chemotherapy as well as diffusion therapy.
People with speech cancer who suffer surgery before receiving radiation care fare better than those who start treatment with chemotherapy, according to a small budding study. Many patients may be hesitant to begin their treatment with an invasive procedure, University of Michigan researchers noted. But advanced surgical techniques can correct patients' chances for survival, the authors well-known in a university word release bonuses. The study was published online Dec 26, 2013 in JAMA Otolaryngology Head and Neck Surgery.
Nearly 14000 Americans will be diagnosed with dialect cancer this year and 2,070 will go to one's final from the disease, according to the American Cancer Society. "To a puerile man with tongue cancer, chemotherapy may durable like a better option than surgery with extensive reconstruction," think over author Dr Douglas Chepeha, a professor of otolaryngology-head and neck surgery at the University of Michigan Medical School, said in the item release hair loss. "But patients with voiced pit cancer can't tolerate induction chemotherapy as well as they can handle surgery with consolidation radiation".
And "Our techniques of reconstruction are advanced and present oneself patients better survival and functional outcomes". The ruminate on involved 19 people with advanced oral cavity gob cancer. All of the participants were given an initial dose of chemotherapy (called "induction" chemotherapy). Patients whose cancer was reduced in dimensions by 50 percent received more chemotherapy as well as diffusion therapy.
среда, 28 февраля 2018 г.
Advanced Cancer Of The Lungs In Some Patients Can Be Cured By The Drug Iressa
Advanced Cancer Of The Lungs In Some Patients Can Be Cured By The Drug Iressa.
Advanced lung cancer is notoriously condensed to treat, but a pair of Japanese scientists reports that a cancer remedy known as Iressa was significantly more able than staple chemotherapy for patients with a firm genetic profile. These patients have an advanced breed of the most common type of lung cancer - non-small stall lung cancer - and a mutation of a protein found on the outside of certain cells that causes them to divide neosizexl shop. This protein - known as epidermal wen factor receptor (EGFR) - is found in unusually weighty numbers on the surface of some cancer cells.
The researchers focused on gefitinib (Iressa), which stops the protein receptor from sending a import to the cancer cells to separate and grow medicine. In their study, reported in the June 24 question of the New England Journal of Medicine, the sedative had a better safety list and improved survival time with no cancer progression in a significantly higher proportion of patients than did standard chemotherapy.
Researchers from the respiratory medicine department at the Tohoku University Hospital in Sendai, Japan chose to probe gefitinib in party because standard cancer treatments -including surgery, emission and chemotherapy - fail to cure most cases of non-small chamber lung cancer. From clinical trials, the researchers also knew that non-small cubicle lung cancers in society with a sensitive EGFR mutation were very responsive to gefitinib, but little was known about the medication's protection profile or effectiveness compared with conventional chemotherapy.
For this reason, Dr Akira Inoue and his colleagues focused on 230 patients with the EGFR modification and metastatic non-small-cell lung cancer; the patients were treated in 43 personal medical facilities between 2006 and 2009 throughout Japan. In a randomized case-control study, half were given gefitinib, while the others received authoritative chemotherapy.
After an standard reinforcement of about 17 months, the research yoke found that while 73,7 percent of the gefitinib patients responded positively to their treatment, only 30,7 percent of the chemotherapy patients did so. The modest survival metre with no cancer progression was significantly higher surrounded by the gefitinib group - 10,8 months, compared to 5,4 months amid the chemotherapy group. In addition, one and two-year survival rates were, respectively, 42,1 percent and 8,4 percent middle those in the gefitinib group, compared to 3,2 and nebbish amongst those in the chemotherapy group.
Advanced lung cancer is notoriously condensed to treat, but a pair of Japanese scientists reports that a cancer remedy known as Iressa was significantly more able than staple chemotherapy for patients with a firm genetic profile. These patients have an advanced breed of the most common type of lung cancer - non-small stall lung cancer - and a mutation of a protein found on the outside of certain cells that causes them to divide neosizexl shop. This protein - known as epidermal wen factor receptor (EGFR) - is found in unusually weighty numbers on the surface of some cancer cells.
The researchers focused on gefitinib (Iressa), which stops the protein receptor from sending a import to the cancer cells to separate and grow medicine. In their study, reported in the June 24 question of the New England Journal of Medicine, the sedative had a better safety list and improved survival time with no cancer progression in a significantly higher proportion of patients than did standard chemotherapy.
Researchers from the respiratory medicine department at the Tohoku University Hospital in Sendai, Japan chose to probe gefitinib in party because standard cancer treatments -including surgery, emission and chemotherapy - fail to cure most cases of non-small chamber lung cancer. From clinical trials, the researchers also knew that non-small cubicle lung cancers in society with a sensitive EGFR mutation were very responsive to gefitinib, but little was known about the medication's protection profile or effectiveness compared with conventional chemotherapy.
For this reason, Dr Akira Inoue and his colleagues focused on 230 patients with the EGFR modification and metastatic non-small-cell lung cancer; the patients were treated in 43 personal medical facilities between 2006 and 2009 throughout Japan. In a randomized case-control study, half were given gefitinib, while the others received authoritative chemotherapy.
After an standard reinforcement of about 17 months, the research yoke found that while 73,7 percent of the gefitinib patients responded positively to their treatment, only 30,7 percent of the chemotherapy patients did so. The modest survival metre with no cancer progression was significantly higher surrounded by the gefitinib group - 10,8 months, compared to 5,4 months amid the chemotherapy group. In addition, one and two-year survival rates were, respectively, 42,1 percent and 8,4 percent middle those in the gefitinib group, compared to 3,2 and nebbish amongst those in the chemotherapy group.
пятница, 7 июля 2017 г.
Node Negative Breast Cancer Is Better Treated By Chemotherapy
Node Negative Breast Cancer Is Better Treated By Chemotherapy.
A chemotherapy regimen already proven standing to other regimens for bust cancer that has layer to the lymph nodes may also do better for some women whose cancers haven't spread, a different study has found. When it came to these "node-negative" cancers, the drug conspiracy of docetaxel, doxorubicin and cyclophosphamide (dubbed TAC) outperformed the syndication of fluorouracil, doxorubicin, and cyclophosphamide (FAC), the Spanish ponder authors said pills4.party. The TAC regimen was better at keeping women humming and disease-free after a median follow up of almost six and a half years, the meditate on found.
So "For those women with higher-risk, node-negative knocker cancer, in which chemotherapy is indicated, TAC is one of the most interesting options," said cram co-author Dr Miguel Martin, a professor of medical oncology at the Hospital General Universitario Gregorio Maranon in Madrid. The observe was funded by the poison maker Sanofi-Aventis - which makes Taxotere, the characterize name for docetaxel - and GEICAM, the Spanish Breast Cancer Research Group malayali penninte natural kuli. The results are published in the Dec 2, 2010 offspring of the New England Journal of Medicine.
To arbitrate which women with heart of hearts cancer would further from adjuvant chemotherapy (typically chemotherapy after surgery), doctors adopt into account a number of risk factors, such as the patient's age, tumor square footage and other characteristics. For the renewed study, the researchers assigned 1060 women with teat cancers that were axillary-node negative who had at least one high-risk factor for recurrence to one of the two curing regimens every three weeks for six cycles after their surgery.
At the 77-month mark, almost 88 percent of the TAC women were among the living and disease-free, compared to intimate to 82 percent of the women in the FAC group. Those in the TAC crowd had a 32 percent reduction in the jeopardize of recurrence, the study authors said. The reduced chance held true even after taking into account a army of high-risk factors, such as age, the women's menopausal prominence and tumor characteristics.
A chemotherapy regimen already proven standing to other regimens for bust cancer that has layer to the lymph nodes may also do better for some women whose cancers haven't spread, a different study has found. When it came to these "node-negative" cancers, the drug conspiracy of docetaxel, doxorubicin and cyclophosphamide (dubbed TAC) outperformed the syndication of fluorouracil, doxorubicin, and cyclophosphamide (FAC), the Spanish ponder authors said pills4.party. The TAC regimen was better at keeping women humming and disease-free after a median follow up of almost six and a half years, the meditate on found.
So "For those women with higher-risk, node-negative knocker cancer, in which chemotherapy is indicated, TAC is one of the most interesting options," said cram co-author Dr Miguel Martin, a professor of medical oncology at the Hospital General Universitario Gregorio Maranon in Madrid. The observe was funded by the poison maker Sanofi-Aventis - which makes Taxotere, the characterize name for docetaxel - and GEICAM, the Spanish Breast Cancer Research Group malayali penninte natural kuli. The results are published in the Dec 2, 2010 offspring of the New England Journal of Medicine.
To arbitrate which women with heart of hearts cancer would further from adjuvant chemotherapy (typically chemotherapy after surgery), doctors adopt into account a number of risk factors, such as the patient's age, tumor square footage and other characteristics. For the renewed study, the researchers assigned 1060 women with teat cancers that were axillary-node negative who had at least one high-risk factor for recurrence to one of the two curing regimens every three weeks for six cycles after their surgery.
At the 77-month mark, almost 88 percent of the TAC women were among the living and disease-free, compared to intimate to 82 percent of the women in the FAC group. Those in the TAC crowd had a 32 percent reduction in the jeopardize of recurrence, the study authors said. The reduced chance held true even after taking into account a army of high-risk factors, such as age, the women's menopausal prominence and tumor characteristics.
понедельник, 19 июня 2017 г.
Omnitarg And Herceptin Could Save Women Without Chemotherapy From Breast Cancer
Omnitarg And Herceptin Could Save Women Without Chemotherapy From Breast Cancer.
Combinations of targeted therapies for an especially bold epitome of heart cancer could potentially usher the seniority of affected patients into remission, researchers at a major bust cancer meeting said Friday. Presenting results from three trials at the annual San Antonio Breast Cancer Symposium, scientists explained that administering two or more drugs designed to explore HER2-positive tumors resulted in much higher alleviation rates than doses of any one dose or guideline chemotherapy alone generic. Given to patients several weeks before cancer surgery, with or without chemotherapy, the medications often shrank tumors dramatically or eradicated them altogether, the researchers said.
HER2-positive cancer is perceptive to a protein called anthropoid epidermal improvement aspect receptor 2, which promotes the growth of malignant cells. Drugs that specifically butt HER2 cells - including Herceptin, Tykerb and Omnitarg - have been proven in operation on these types of tumors, which incline to be more aggressive than other breast cancers provillusshop com. "I fantasize it's a very exciting era, because we've gone from a very lethal generation - to a point where we might be able to cure this disease," said Dr Neil Spector, a professor of panacea at Duke University Medical Center, who moderated the symposium session.
Using Tykerb and Herceptin combined with chemotherapy before surgery, researchers followed 2,500 women with antique mamma cancer at 85 facilities throughout Germany. About half of these patients achieved release before surgery, said Dr Michael Untch, grey matter of the multidisciplinary core cancer bailiwick at Helios Clinic in Berlin. "In a majority of these patients, we could do breast-conserving surgery where earlier they were candidates for mastectomy".
The team will continue following the patients to visit with if remission at surgery affects their outcome. Another work showed the combination of Omnitarg and Herceptin, when given with the chemotherapy drug docetaxel, eradicated 46 percent of tumors, 50 percent more than the results achieved without Omnitarg. Also, 17 percent of tumors were eradicated by combining the two targeted drugs and skipping chemotherapy, the researchers said.
Combinations of targeted therapies for an especially bold epitome of heart cancer could potentially usher the seniority of affected patients into remission, researchers at a major bust cancer meeting said Friday. Presenting results from three trials at the annual San Antonio Breast Cancer Symposium, scientists explained that administering two or more drugs designed to explore HER2-positive tumors resulted in much higher alleviation rates than doses of any one dose or guideline chemotherapy alone generic. Given to patients several weeks before cancer surgery, with or without chemotherapy, the medications often shrank tumors dramatically or eradicated them altogether, the researchers said.
HER2-positive cancer is perceptive to a protein called anthropoid epidermal improvement aspect receptor 2, which promotes the growth of malignant cells. Drugs that specifically butt HER2 cells - including Herceptin, Tykerb and Omnitarg - have been proven in operation on these types of tumors, which incline to be more aggressive than other breast cancers provillusshop com. "I fantasize it's a very exciting era, because we've gone from a very lethal generation - to a point where we might be able to cure this disease," said Dr Neil Spector, a professor of panacea at Duke University Medical Center, who moderated the symposium session.
Using Tykerb and Herceptin combined with chemotherapy before surgery, researchers followed 2,500 women with antique mamma cancer at 85 facilities throughout Germany. About half of these patients achieved release before surgery, said Dr Michael Untch, grey matter of the multidisciplinary core cancer bailiwick at Helios Clinic in Berlin. "In a majority of these patients, we could do breast-conserving surgery where earlier they were candidates for mastectomy".
The team will continue following the patients to visit with if remission at surgery affects their outcome. Another work showed the combination of Omnitarg and Herceptin, when given with the chemotherapy drug docetaxel, eradicated 46 percent of tumors, 50 percent more than the results achieved without Omnitarg. Also, 17 percent of tumors were eradicated by combining the two targeted drugs and skipping chemotherapy, the researchers said.
четверг, 15 октября 2015 г.
Doctors Recommend A New Complex Cancer Treatment
Doctors Recommend A New Complex Cancer Treatment.
Women with unfriendly titty cancer who receive federation targeted therapy with chemotherapy prior to surgery have a slight improved chance of staying cancer-free, researchers say. However, the change for the better was not statistically significant and the jury is still out on combination treatment, said cause researcher Dr Martine Piccart-Gebhart, chair of the Breast International Group, in Brussels scriptovore. "I don't contemplate that tomorrow we should exchange to a new standard of care.
Piccart-Gebhart presented her findings Wednesday at the 2013 San Antonio Breast Cancer Symposium, alongside other inquiry that investigated ways to give a new lease of treatment for women with HER2-positive core cancer. This aggressive form of cancer is linked to a genetic irregularity. Other researchers reported the following skinception cold pressed cosmetic argan oil at amazon india. The targeted numb trastuzumab (Herceptin) worked better in HER2-positive teat cancer tumors containing far up levels of unsusceptible cells.
A combination of the chemotherapy drugs docetaxel and carboplatin with Herceptin appeared to be the best postsurgery care option. Overall, the studies were cogent news for women with HER2-positive breast cancer, which second-hand to be one of the most fatal forms of the disease. Researchers reported long-term survival rates higher than 90 percent for women treated using the targeted group therapy drugs. "That tells you these treatments are very, very effective," Piccart-Gebhart said.
Piccart-Gebhart's combo targeted remedy trouble is evaluating whether the HER2-targeted drugs Herceptin and lapatinib (Tykerb) exert oneself better when combined on clip of standard chemotherapy. The distress involved 455 patients with HER2-positive heart of hearts cancer with tumors larger than 2 centimeters. The women were given chemotherapy erstwhile to surgery along with either Herceptin, Tykerb, or a combination of the two targeted drugs. They also were treated after surgery with whichever targeted treatment they had been receiving.
Piccart-Gebhart reported that 84 percent of the patients who received the association targeted psychotherapy between 2008 and 2010 have remained cancer-free, compared with 76 percent who only received Herceptin. "It's too antique today to require this dual treatment saves more lives. We can't about that on the basis of this trial". The drawbacks of this array therapy are cost and side effects, Piccart-Gebhart said.
Women with unfriendly titty cancer who receive federation targeted therapy with chemotherapy prior to surgery have a slight improved chance of staying cancer-free, researchers say. However, the change for the better was not statistically significant and the jury is still out on combination treatment, said cause researcher Dr Martine Piccart-Gebhart, chair of the Breast International Group, in Brussels scriptovore. "I don't contemplate that tomorrow we should exchange to a new standard of care.
Piccart-Gebhart presented her findings Wednesday at the 2013 San Antonio Breast Cancer Symposium, alongside other inquiry that investigated ways to give a new lease of treatment for women with HER2-positive core cancer. This aggressive form of cancer is linked to a genetic irregularity. Other researchers reported the following skinception cold pressed cosmetic argan oil at amazon india. The targeted numb trastuzumab (Herceptin) worked better in HER2-positive teat cancer tumors containing far up levels of unsusceptible cells.
A combination of the chemotherapy drugs docetaxel and carboplatin with Herceptin appeared to be the best postsurgery care option. Overall, the studies were cogent news for women with HER2-positive breast cancer, which second-hand to be one of the most fatal forms of the disease. Researchers reported long-term survival rates higher than 90 percent for women treated using the targeted group therapy drugs. "That tells you these treatments are very, very effective," Piccart-Gebhart said.
Piccart-Gebhart's combo targeted remedy trouble is evaluating whether the HER2-targeted drugs Herceptin and lapatinib (Tykerb) exert oneself better when combined on clip of standard chemotherapy. The distress involved 455 patients with HER2-positive heart of hearts cancer with tumors larger than 2 centimeters. The women were given chemotherapy erstwhile to surgery along with either Herceptin, Tykerb, or a combination of the two targeted drugs. They also were treated after surgery with whichever targeted treatment they had been receiving.
Piccart-Gebhart reported that 84 percent of the patients who received the association targeted psychotherapy between 2008 and 2010 have remained cancer-free, compared with 76 percent who only received Herceptin. "It's too antique today to require this dual treatment saves more lives. We can't about that on the basis of this trial". The drawbacks of this array therapy are cost and side effects, Piccart-Gebhart said.
понедельник, 1 июня 2015 г.
Surgery to treat rectal cancer
Surgery to treat rectal cancer.
For many rectal cancer patients, the thought of surgery is a worrisome reality, given that the functioning can significantly mar both bowel and sexual function. However, a strange study reveals that some cancer patients may fare just as well by forgoing surgery in favor of chemotherapy/radiation and "watchful waiting". The discovery is based on a look over of data from 145 rectal cancer patients, all of whom had been diagnosed with grade I, II or III disease revitol. All had chemotherapy and radiation.
But about half had surgery while the others staved off the mode in favor of rigorous tracking of their condition course - sometimes called "watchful waiting review. We assume that our results will encourage more doctors to consider this 'watch-and-wait' approach in patients with clinical undiminished response as an alternative to immediate rectal surgery, at least for some patients," chief study author Dr Philip Paty said in a word release from the American Society of Clinical Oncology (ASCO).
For many rectal cancer patients, the thought of surgery is a worrisome reality, given that the functioning can significantly mar both bowel and sexual function. However, a strange study reveals that some cancer patients may fare just as well by forgoing surgery in favor of chemotherapy/radiation and "watchful waiting". The discovery is based on a look over of data from 145 rectal cancer patients, all of whom had been diagnosed with grade I, II or III disease revitol. All had chemotherapy and radiation.
But about half had surgery while the others staved off the mode in favor of rigorous tracking of their condition course - sometimes called "watchful waiting review. We assume that our results will encourage more doctors to consider this 'watch-and-wait' approach in patients with clinical undiminished response as an alternative to immediate rectal surgery, at least for some patients," chief study author Dr Philip Paty said in a word release from the American Society of Clinical Oncology (ASCO).
воскресенье, 14 декабря 2014 г.
The Impact Of Rituxan For The Treatment Of Follicular Lymphoma
The Impact Of Rituxan For The Treatment Of Follicular Lymphoma.
New fact-finding provides more show that treating positive lymphoma patients with an up-market drug over the long term helps them go longer without symptoms. But the drug, called rituximab (Rituxan), does not seem to significantly gain life span, raising questions about whether it's value taking. People with lymphoma who are in maintenance treatment "really need a analysis with their oncologist," said Dr Steven T Rosen, gaffer of the Robert H Lurie Comprehensive Cancer Center at Northwestern University in Chicago vitoviga. The memorize involved man with follicular lymphoma, one of the milder forms of non-Hodgkin lymphoma, a sitting that refers to cancers of the immune system.
Though it can be fatal, most population live for at least 10 years after diagnosis. There has been think through over whether people with the disease should take Rituxan as maintenance therapy after their original chemotherapy. In the study, which was funded in part by F Hoffmann-La Roche, a pharmaceutical assemblage that sells Rituxan, violently half of the 1019 participants took Rituxan, and the others did not klonopin prices. All beforehand had taken the drug right after receiving chemotherapy.
In the next three years, the analysis found, people taking the treat took longer, on average, to develop symptoms. Three-quarters of them made it to the three-year consequence without progression of their illness, compared with about 58 percent of those who didn't let in the drug. But the death rank over three years remained about the same, according to the report, published online Dec 21 2010 in The Lancet.
New fact-finding provides more show that treating positive lymphoma patients with an up-market drug over the long term helps them go longer without symptoms. But the drug, called rituximab (Rituxan), does not seem to significantly gain life span, raising questions about whether it's value taking. People with lymphoma who are in maintenance treatment "really need a analysis with their oncologist," said Dr Steven T Rosen, gaffer of the Robert H Lurie Comprehensive Cancer Center at Northwestern University in Chicago vitoviga. The memorize involved man with follicular lymphoma, one of the milder forms of non-Hodgkin lymphoma, a sitting that refers to cancers of the immune system.
Though it can be fatal, most population live for at least 10 years after diagnosis. There has been think through over whether people with the disease should take Rituxan as maintenance therapy after their original chemotherapy. In the study, which was funded in part by F Hoffmann-La Roche, a pharmaceutical assemblage that sells Rituxan, violently half of the 1019 participants took Rituxan, and the others did not klonopin prices. All beforehand had taken the drug right after receiving chemotherapy.
In the next three years, the analysis found, people taking the treat took longer, on average, to develop symptoms. Three-quarters of them made it to the three-year consequence without progression of their illness, compared with about 58 percent of those who didn't let in the drug. But the death rank over three years remained about the same, according to the report, published online Dec 21 2010 in The Lancet.
Подписаться на:
Сообщения (Atom)